Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation

Figure 2

The effect of TFM-C on CIA. A. Clinical scores of CIA in DBA1/J mice treated with 10 μg/g TFM-C (closed circles), celecoxib (open triangles) or vehicle (open squares) every other day from 21 days after immunization. The data shown are pooled from two similar experiments. Error bars represent + SEM of 10 to 12 mice per group. * P < 0.05 compared with control group. * P < 0.05 compared with both control and celecoxib-treated groups. B. Quantification of histological assessment of joints 37 days after induction of CIA. Result shown is the mean + SEM of five mice per group. * P < 0.05, TFM-C-treated versus vehicle-treated group. * P < 0.05, celecoxib-treated versus TFM-C-treated group. C. Representative histological feature of joints in vehicle-treated (left), TFM-C-treated (right) and celecoxib-treated (middle) mice. (H&E stained; original magnification × 40). D. The effect of TFM-C on CII-specific response. CII-specific antibody responses in vehicle- (open bars), TFM-C- (filled bars) and celecoxib-treated (gray bars) group. Individual serum samples were obtained at Day 37 after the induction of arthritis and were analyzed as indicated in Materials and Methods. Data represent the mean + SEM of five mice per group.

Back to article page